These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17117598)

  • 21. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
    Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
    Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
    Kane SV; Bjorkman DJ
    Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
    Olmstead J
    J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
    Saini SD; Waljee AK; Higgins PD
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1143-51. PubMed ID: 22610010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
    Bresci G; Parisi G; Capria A
    Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis.
    Casellas F; Vaquero E; Armengol JR; Malagelada JR
    Hepatogastroenterology; 1999; 46(28):2343-6. PubMed ID: 10521994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis.
    Manguso F; Balzano A
    Aliment Pharmacol Ther; 2007 Jul; 26(1):21-9. PubMed ID: 17555418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T; Probert CS; Keshav S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mesalamine wars heat up-enter balsalazide.
    Cohen RD
    Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
    [No Abstract]   [Full Text] [Related]  

  • 35. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
    Hanauer SB
    Am J Gastroenterol; 2003 Jan; 98(1):215-6. PubMed ID: 12526968
    [No Abstract]   [Full Text] [Related]  

  • 37. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
    Tursi A
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New lessons: classic treatments, expanding options in ulcerative colitis.
    Hanauer SB
    Colorectal Dis; 2006 May; 8 Suppl 1():20-4. PubMed ID: 16594960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.